TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06937086: A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 350 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT06937086 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06937086 Rescue Dossier →